SCHEMBL9933442

SCHEMBL9933442

C[C@H]1CN(C(=O)O)CCN1Cc1ccccn1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.49
KDM4E B2RXH2 6/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
MAPT P10636 1/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
LMNA P02545 1/20 0.46
NPSR1 Q6W5P4 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
POLB P06746 1/20 0.44
CHRM1 P11229 1/20 0.44
HRH3 Q9Y5N1 2/20 0.43
CACNA1G O43497 1/20 0.43
CACNA1H O95180 1/20 0.43
CACNA1I Q9P0X4 1/20 0.43
SLC6A7 Q99884 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9933469 1.00 ALDH1A1 (0.49) ALDH1A1KDM4EL3MBTL1MAPTTSHR
SCHEMBL30163900 1.00 ALDH1A1 (0.49) ALDH1A1KDM4EL3MBTL1MAPTTSHR
SCHEMBL29232213 0.84 CHRM1 (0.40) KDM4EPOLBCHRM1SLC6A7
SCHEMBL29232365 0.84 CHRM1 (0.40) KDM4EPOLBCHRM1SLC6A7
SCHEMBL29232214 0.84 CHRM1 (0.40) KDM4EPOLBCHRM1SLC6A7
SCHEMBL30918491 0.83 GPR119 (0.48) ALDH1A1KDM4EPOLB
SCHEMBL9963100 0.83 GPR119 (0.48) ALDH1A1KDM4EPOLB
SCHEMBL9963102 0.83 GPR119 (0.48) ALDH1A1KDM4EPOLB
SCHEMBL3322121 0.81 CHRM1 (0.55) ALDH1A1MAPTLMNACHRM1
SCHEMBL8033959 0.80 CHRM1 (0.54) ALDH1A1MAPTLMNACHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2470021-B1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME (US) 2014-10-22 EP disclosed
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 ALDH1A1 534/4885KDM4E 3804/4885L3MBTL1 4267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.